Systemic Thrombolytic Therapy for Ischemic Stroke in the Course of Anticoagulants
https://doi.org/10.23934/2223-9022-2021-10-3-598-603
Abstract
This article reports the first experience of the N.V. Sklifosovsky Research Institute for Emergency Medicine in reperfusion therapy for ischemic stroke in a patient taking oral anticoagulant.
About the Authors
L. Kh.-B. Akhmatkhanova
N.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Health Department
Russian Federation
Russian Federation
Neurologist of the Neurological Department for Patients with Acute Cerebrovascular Accidents
3 B. Sukharevskaya Sq., Moscow 129090, Russian Federation
G. R. Ramazanov
N.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Health Department
Russian Federation
Russian Federation
Candidate of Medical Sciences, Head of the Scientific Department of Emergency Neurology and Rehabilitation Treatment, Neurologist at the Neurological Department with the Intensive Care Unit for Patients with Acute Cerebrovascular Accidents
3 B. Sukharevskaya Sq., Moscow 129090, Russian Federation
E. V. Klychnikova
N.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Health Department
Russian Federation
Russian Federation
Head of the Scientific Clinical and Biochemical Laboratory for Emergency Research Methods
3 B. Sukharevskaya Sq., Moscow 129090, Russian Federation
R. Sh. Muslimov
N.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Health Department
Russian Federation
Russian Federation
Leading Researcher of the Department of Diagnostic Radiology
3 B. Sukharevskaya Sq., Moscow 129090, Russian Federation
M. V. Parkhomenko
N.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Health Department
Russian Federation
Russian Federation
Doctor for Endovascular Diagnosis and Treatment, Head of the Department of X-ray Surgical Methods of Diagnosis and Treatment
3 B. Sukharevskaya Sq., Moscow 129090, Russian Federation
References
1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361(12):1139–1151. PMID: 19717844 https://doi.org/10.1056/NEJMoa0905561
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883–891. PMID: 21830957 https://doi.org/10.1056/NEJMoa1009638
3. Granger ChB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981–992. PMID: 21870978 https://doi.org/10.1056/NEJMoa1107039
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart Disease and Stroke Statistics--2014 Update: A Report from the American Heart Association. Circulation. 2014;129(3):e28–e292. PMID: 24352519 https://doi.org/10.1161/01.cir.0000441139.02102.80
5. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–e99. PMID: 29367334 https://doi.org/10.1161/STR.0000000000000158
6. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1587. PMID: 7477192 https://doi.org/10.1056/NEJM199512143332401
7. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N Engl J Med. 2008;359(13):1317–1329. PMID: 18815396 https://doi.org/10.1056/NEJMoa0804656
8. Pollack ChV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. N Engl J Med. 2017;377(5):431–441. PMID: 28693366 https://doi.org/10.1056/NEJMoa1707278
9. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. J Am Coll Cardiol. 2020;76(5):594–622. PMID: 32680646 https://doi.org/10.1016/j.jacc.2020.04.053
10. von Wowern F, Brizzi M, Holst J. Reversal of the anticoagulation effects of dabigatran etexilate by idarucizumab in three patients needing urgent surgical intervention and one case of intravenous thrombolysis in ischaemic stroke. Eur J Case Rep Intern Med. 2017;4(4):000569. PMID: 30755937 https://doi.org/10.12890/2017_000569
11. Reperfuzionnaya terapiya ishemicheskogo insul’ta. Klinicheskiy protokol. Moscow; 2019. (in Russ.) Available at: https://nevrologia.info/upload/iblock/8dc/8dc289e4f0d6defbe6141bf55db7ac3f.pdf [Accessed 10 Dec 2020]
Review
For citations:
Akhmatkhanova L.Kh., Ramazanov G.R., Klychnikova E.V., Muslimov R.Sh., Parkhomenko M.V. Systemic Thrombolytic Therapy for Ischemic Stroke in the Course of Anticoagulants. Russian Sklifosovsky Journal "Emergency Medical Care". 2021;10(3):598-603. https://doi.org/10.23934/2223-9022-2021-10-3-598-603
Views:
644
Email this article 